Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial highlights key recent findings in cardiovascular epidemiology, emphasizing the importance of targeted prevention, environmental risk factors, and updated management strategies for various cardiovascular conditions.
The first study to forecast the future incidence of cardiovascular disease (CVD) in terms of health and economic outcomes in Australia is here presented, capturing direct healthcare costs and indirect costs using the human capital approach: regardless of the figures, this article highlights that policies that support the targeted allocation of funds and greater prevention would yield a better health outcome, quality of life and productivity, and consequently reduce future chronic healthcare costs.1 As per the scenario analysis, only a 10% decrease in total cardiovascular risk within the primary prevention setting would significantly reduce cardiovascular events and costs, which is in line with the recent European Guidelines on CVD prevention. Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome, whose prevalence has increased in the last decades and it is expected to overcome that of HF with reduced ejection fraction in the near future. HFpEF patients are frequently elderly women, with higher body mass index, greater prevalence of systolic hypertension and atrial fibrillation and presenting with a high rate of non-cardiac comorbidities, which adversely influence myocardial remodelling and outcome.2 The present review underlines the need of a universal definition to precisely define the epidemiological boundaries for HFpEF.3 Future trials should be tailored on specific aetiologies (i.e. resistant hypertension, cardiac amyloidosis, etc.), specific patient subsets (women, obese patients, and elderly), or comorbidities (sleep disorders, renal failure, and diabetes) to eventually affect prognosis. Although relatively uncommon or rare, cardiomyopathies (CMPs) represent a substantial component of the CVD spectrum, and all cardiologists should expect to encounter these individuals routinely in clinical practice. Hence, suspicion should be kept high and trigger second-line investigations. Even though it is unrealistic that each physician may reach a final diagnosis, particularly with rare conditions, suspicion, and appropriate referral are the keys to prevent neglect and diagnostic delay. A pre-specified diagnostic work-up is highly recommended to transfer a rigorous methodological approach into daily practice.4 The coronavirus disease 2019 (COVID-19) pandemic has resulted in excess mortality due to both COVID-19 directly and other conditions, including CVD.5 According to a here presented meta-analysis, which included 15 studies and 27 421 patients, in-hospital mortality doubled among patients admitted with CVD relative to periods outside the pandemic, independent of co-infection with COVID-19. This effect was larger in studies with the biggest decline in admission rates, suggesting a sicker cohort of patients in this period.6 However, studies were generally poorly conducted, and there is a need for further well-designed studies to establish the full extent of mortality not directly related to COVID-19 infection. The analysis of the temporal, global, and regional (195 countries) patterns of aortic aneurysm (thoracic and abdominal) mortality showed a decline in mortality, which was affected by socio-demographic index, healthcare access, and quality index. In addition, high LDL cholesterol, smoking habits, and high fasting plasma glucose were positively related to age-standardized age-adjusted aortic aneurysm mortality. 7 A prospective study involving a large patient population with clinically manifest vascular disease, patients were screened at baseline for abdominal aortic aneurysm (AAA) by abdominal ultrasonography:8 the prevalence was larger in men than in women (2.5% vs. 0.7%), but it declined from 1997 until 2017 in men aged 70–79 years from 8.1% to 3.2% and in men aged 60–69 years from 5.7% to 1.0%. At 15-year follow-up, the detection of AAA was associated with lower survival with respect to those without AAA, suggesting the screening for AAA in patients with vascular disease may be cost-effective, but this remains to be determined. Infective endocarditis (IE) accounts for significant morbidity and mortality. Timely diagnosis and prompt treatment are of paramount importance for optimal patient outcome. Here, two studies based on the Global Burden of Disease Study 2019 evaluated the epidemiology of the IE and the key role of optimal quality of care. Results based on the Global Burden of Disease Study 2019 showed that the incidence and mortality of IE have continued to rise in the past 30 years, by 2.3 times for both men and women, which reflected the population growth and especially in the regions with the higher socio-demographic index.9 Degenerative valvular diseases, implantable devices, intravenous medication, congenital heart disease, diabetes, and cancer have replaced rheumatic heart disease as the main risk factors for IE. Healthcare-associated IE accounts for an increasing proportion of cases, and the affected patients are older and more severely ill than in the past, usually accompanied by many comorbidities.10 Also in a subsequent analysis, the all-ages incidence rate of IE was estimated to increase significantly from 1990 to 2019, but the mortality rate did not change. As expected, the quality of care was higher in high-income countries than in low-income countries, highlighting the necessity of improving the IE quality of care, mainly by timely case detection, adherence to antibiotic prophylaxis guidelines, utilizing targeted antibiotics and advanced treatments, in the African region.11 Low electrocardiographic QRS voltages (LQRSV) are thought to be affected by conditions that impair either the generation or the transmission of electrical signals from the heart to the electrodes applied to body surface, such as cardiac and non-cardiac conditions. Here, a review summarizes the diagnostic and prognostic value of LQRSV in cardio (i.e. arrhythmogenic cardiomyopathy, non-ischaemic left ventricular scar, amyloidosis and infiltrative disorders, hypertrophic CMP, dilated CMP, and Takotsubo syndrome) reporting the new evidence, primarily based on advanced imaging studies, supporting the clinical utility of this parameter.12 Chronic exposure to environmental noise stress, such as traffic or aircraft noise, has been associated with increased cardiovascular risk including hypertension: in fact, it causes vascular changes like classical risk factors, but the underlying pathophysiological mechanisms are not fully understood.13 In male hypertensive patients, a vasoconstrictive response in the systemic circulation after aircraft noise exposure accompanied by a decrease in the cardiac index was here observed. Such a haemodynamic response pattern to short-term noise was not seen in male normotensive subjects, suggesting a higher sensitivity to noise n hypertensive subjects.14 Acute effects of ambient particulate matter (PM), observed from hours to days after exposure, have been extensively documented, with the CVD consequences shown to be equal to or even more severe than those due to respiratory diseases.15 Here, a significant short-term association of PM with total CVD, cardiac diseases, ischaemic heart diseases, myocardial infarction, and ischaemic stroke was confirmed, with evidence of an immediate effect on the same day of exposure. A highly significant association with admissions for heart failure lasting over 1 week after exposure, and atrial fibrillation, lasting 2 days after exposure was also observed. The strength of association was comparable among areas with different degrees of urbanization and the exposure–response relationships were non-linear. Finally, elderly patients were the most vulnerable to the acute effects of PM, while we did not find substantial differences by sex.16 This consensus document is proposed to clinicians to provide the whole spectrum of deep vein thrombosis management as an update to the 2017 consensus document. New data guiding clinicians in indicating extended anticoagulation, management of patients with cancer, and prevention and management of post-thrombotic syndrome are presented. More data on the benefit and safety of non-vitamin K antagonists oral anticoagulants are highlighted, along with the arrival of new antidotes for severe bleeding management.17 Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Hálasz et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: